Loading...
•
Mar 31, 2024
Intensity Therapeutics Q1 2024 Earnings Report
Announced first quarter 2024 financial results and provided a corporate update.
Key Takeaways
Intensity Therapeutics reported a net loss of $4.6 million for the first quarter of 2024, with research and development expenses increasing to $2.8 million and general and administrative expenses rising to $1.9 million. As of March 31, 2024, cash, cash equivalents, and marketable debt securities totaled $10.5 million, expected to fund operations through the end of the first quarter of 2025.
INT230-6 continues to advance into late-stage clinical programs in sarcoma and breast cancer.
Initiation of a Phase 3 study (INVINCIBLE-3) testing INT230-6 as a monotherapy for soft tissue sarcoma is planned for mid-2024.
Initiation of a Phase 2/3 program (INVINCIBLE-4) testing INT230-6 in combination with SOC for triple negative breast cancer is planned for mid-2024.
Cash and investments of $10.5 million are expected to fund operations through the end of the first quarter of 2025.
Intensity Therapeutics
Intensity Therapeutics
Forward Guidance
Intensity Therapeutics expects its cash and investments of $10.5 million to be sufficient to fund operations through the end of the first quarter of 2025.
Positive Outlook
- Sufficient cash to fund operations through Q1 2025